|
Gene ID
|
CpGs
|
Control %
|
Patient %
|
Difference
|
P value
|
F test value
|
|---|
|
SARDH
|
3
|
88
|
64
|
− 24
|
6.52 × 10–3
|
F(1,14) = 10.19
|
|
MAST4
|
4
|
82
|
61
|
− 21
|
4.72 × 10–3
|
F(1,14) = 11.26
|
|
GRAMD4
|
4
|
64
|
44
|
− 20
|
4.80 × 10–2
|
F(1,13) = 4.76
|
|
GNG7
|
7
|
64
|
45
|
− 19
|
2.94 × 10–2
|
F(1,17) = 5.66
|
|
RP11-566K11.2
|
7
|
46
|
28
|
− 18
|
6.01 × 10–2
|
F(1,15) = 18.70
|
|
ZNF714
|
6
|
12
|
42
|
+ 30
|
1.12 × 10–2
|
F(1,16) = 8.22
|
|
DNAJB13
|
5
|
41
|
69
|
+ 28
|
4.57 × 10–4
|
F(1,15) = 19.91
|
|
COX19
|
6
|
11
|
32
|
+ 21
|
1.96 × 10–2
|
F(1,15) = 6.82
|
|
CARD8
|
3
|
77
|
98
|
+ 21
|
7.06 × 10–4
|
F(1,13) = 19.44
|
|
C8orf31
|
9
|
43
|
64
|
+ 21
|
4.75 × 10–2
|
F(1,13) = 4.79
|
- For each gene, the number of CpGs within the fragment, and methylation percentages of control subjects and ME/CFS patients are shown, with the differences (− is hypo-methylated, + is hyper-methylated). Significance scores are shown as P values and corresponding F value (degrees of freedom in brackets). A full list is available in Additional file 1: Excel file ‘DMAP_Gene_Full’.
